PharmaSphere: North American Market Access Strategy

1
PharmaSphere North American Market Access
Strategy
Single User License - 2995 Site User License -
5990 Corporate User License - 8985 Publication
Date - Jun 2015 Pages - 101 To know more
details, email to debora_at_reportstack.com
2
Summary

• This report provides a strategic analysis of the
  pharmaceutical market landscape in this
  geographic region, and the impact of the current
  and emerging market access strategies that the
  pharmaceutical industry is using for its for new
  and existing drugs. It discusses the regulatory
  requirements for pharmaceutical products in North
  American, key health insurance trends, recent
  government healthcare reforms, and general
  industry trends. It also describes the
  macroeconomic factors that impact the
  commercialization of new pharmaceutical products.

3
Key Questions Answered

• What are the main factors influencing market
  access in North America?
• How do demographic trends impact market access in
  Canada and Mexico?
• What are the important elements of the healthcare
  systems in the US, Canada, and Mexico?
• How important is health technology assessment
  (HTA)? What are the key processes leading up to a
  successful HTA in North America?
• What are the different pricing and reimbursement
  procedures adopted by regulators in North
  America?
• How have cost-containment pressures impacted the
  commercialization of new pharmaceutical products?

4
Key Benefits

• Identify the key decision makers in various
  countries in the North American region, including
  the US, Canada, and Mexico
• Understand the key causes, concerns, drivers, and
  trends that characterize the market access
  process
• Analyze the impact of recent healthcare reform
  legislation on market access procedures
• Identify the key factors in the market access
  process, such as pricing, reimbursement,
  co-payments, discounts, and pharma economic
  guidelines
• Understand the impact of macroeconomic factors,
  such as healthcare expenditures, foreign direct
  investment (FDI), and population demographics on
  the market access process.

5
Companies Mentioned

• Amgen,
• Ariad,
• Bayer,
• Biogen,
• BMS,
• Dendreon,
• Exelixis,
• Gilead,
• Hospira,
• JJ,
• Merck,
• Mylan,
• Novartis,
• Onyx, etc

6
If you are interested...
Contact Debora White Email
debora_at_reportstack.com Ph1-888-789-6604 http/
/www.reportstack.com